Alterity Therapeutics (ATHE) Research & Development (2014 - 2025)
Alterity Therapeutics (ATHE) posted quarterly Research & Development of -$9.5 million for Q4 2025, down 39.81% year-over-year from -$15.7 million in Q4 2024, and down 39.81% quarter-over-quarter from -$6.8 million in Q4 2024.
Alterity Therapeutics (ATHE) Research & Development (2014 - 2025) Analysis & Trends
Alterity Therapeutics' Research & Development history runs 11 years deep, the most recent figure standing at -$9.5 million for Q4 2025.
- In Q4 2025, Research & Development fell 39.81% year-over-year to -$9.5 million; the TTM figure through Dec 2025 stood at -$33.8 million (down 1.46% YoY), while the FY2025 annual figure was $9.2 million, down 100.0% from the prior year.
- Research & Development for Q4 2025 stood at -$9.5 million, down from -$6.8 million in the prior quarter.
- The five-year high for Research & Development was -$6.8 million in Q4 2024, with the low at -$9.5 million in Q4 2025.
- The 5-year median for Research & Development is -$9.0 million (2021), against an average of -$8.6 million.
- The sharpest annual moves came in 2024 and 2025: Research & Development increased 18.23% in 2024, then sank 39.81% in 2025.
- Alterity Therapeutics' Research & Development stood at -$9.0 million in 2021, then decreased by 2.99% to -$9.3 million in 2022, then advanced by 10.48% to -$8.3 million in 2023, then increased by 18.23% to -$6.8 million in 2024, then plunged by 39.81% to -$9.5 million in 2025.
- Business Quant data shows ATHE's Research & Development at -$9.5 million in Q4 2025, -$6.8 million in Q4 2024, and -$8.3 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.41 Bn | 131.56 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 86.14 Bn | 78.15 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 65.52 Bn | 60.34 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 58.21 Bn | 53.07 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 27.95 Bn | 9.56 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.46 Bn | - | 97.90 Mn |
| 10 | Alterity Therapeutics | 49.04 Mn | 16.74 Mn | - | -9.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -9.47 Mn |
| Dec 31, 2024 | -6.77 Mn |
| Dec 31, 2023 | -8.28 Mn |
| Dec 31, 2022 | -9.25 Mn |
| Dec 31, 2021 | -8.98 Mn |
| Dec 31, 2019 | 3.93 Mn |
| Dec 31, 2018 | -4.23 Mn |
| Dec 31, 2017 | -1.76 Mn |
| Dec 31, 2016 | 2.87 Mn |
| Dec 31, 2015 | -7.08 Mn |
| Dec 31, 2014 | -9.51 Mn |